Clinical trials are starting in the U.S. for a combination vaccine made by German biotech company Biontech and its partner Pfizer against Corona and the flu.
The combination vaccine candidate combines the already approved Corona vaccine against BA.4 and BA.5 from both Biontech and Pfizer with a flu vaccine candidate from Pfizer that is currently being tested in Phase 3 clinical trial.
180 people in the U.S. testing a combination of Corona and influenza vaccine
The Phase 1 trial of the combination vaccine is expected to enroll 180 people in the U.S. between 18 and 64, and the first subject has already been vaccinated this week. “Combining both indications in one vaccine approach, we want to offer people an efficient way to immunize themselves against two serious respiratory diseases,” says Biontech CEO Ugur Sahin.
- source: vienna.at/picture: pixabay.com
This post has already been read 34 times!